Levomethadone

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Levomethadone
Levomethadone structure.svg
Systematic (IUPAC) name
(6R)-6-(dimethylamino)-4,4-diphenyl-3-heptanone
Clinical data
AHFS/Drugs.com International Drug Names
Legal status Schedule II (US)
Class A (UK)
Schedule I (UN)
Routes Oral, IV, IM, SC, IT[1]
Pharmacokinetic data
Bioavailability High[1]
Protein binding 60-90%[1]
Half-life ~18 hours[1]
Identifiers
CAS number 125-58-6
5967-73-7 (HCl)
ATC code N07BC05
PubChem CID 22267
ChemSpider 20904
Chemical data
Formula C21H27NO 
Mol. mass 309.445 g/mol

Levomethadone (INN; L-Polamidon, L-Polamivet, Levadone, Levothyl), or levamethadone, is a synthetic opioid analgesic and antitussive which is marketed in Europe and is used for pain management and in opioid maintenance therapy.[1][2][3] In addition to being used as a pharmaceutical drug itself, levomethadone, or R-(-)-methadone, is the active enantiomer of methadone,[2] having approximately 50x the potency of the S-(+)-enantiomer as well as greater μ-opioid receptor selectivity.[1][4] Accordingly, it is about twice as potent as methadone by weight and its effects are virtually identical in comparison.[5][6] In addition to its activity at the opioid receptors, levomethadone has been found to act as a weak competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor complex[7] and as a potent noncompetitive antagonist of the α3β4 nicotinic acetylcholine (nACh) receptor.[8]

There is now an asymmetric synthesis[9] available to prepare both levomethadone [R-(-)-methadone] and dextromethadone [S-(+)-methadone].[10]

See also[edit]

References[edit]

  1. ^ a b c d e f Helmut Buschmann (20 December 2002). Analgesics: From Chemistry and Pharmacology to Clinical Application. Wiley-VCH. p. 196. ISBN 978-3-527-30403-5. Retrieved 17 May 2012. 
  2. ^ a b F.. Macdonald (1997). Dictionary of Pharmacological Agents. CRC Press. p. 1294. ISBN 978-0-412-46630-4. Retrieved 17 May 2012. 
  3. ^ Index Nominum 2000: International Drug Directory. Taylor & Francis US. 2000. p. 605. ISBN 978-3-88763-075-1. Retrieved 17 May 2012. 
  4. ^ Renate Förch; Holger Schönherr; A. Tobias A. Jenkins (11 August 2009). Surface Design: Applications in Bioscience and Nanotechnology. Wiley-VCH. p. 193. ISBN 978-3-527-40789-7. Retrieved 17 May 2012. 
  5. ^ Eduardo Bruera; Sriram Yennurajalingam (16 August 2011). Oxford American Handbook of Hospice and Palliative Medicine. Oxford University Press. p. 43. ISBN 978-0-19-538015-6. Retrieved 17 May 2012. 
  6. ^ Verthein U, Ullmann R, Lachmann A, et al. (November 2005). "The effects of racemic D,L-methadone and L-methadone in substituted patients--a randomized controlled study". Drug and Alcohol Dependence 80 (2): 267–71. doi:10.1016/j.drugalcdep.2005.04.007. PMID 15916866. 
  7. ^ Eric C. Strain; Maxine L. Stitzer (4 November 2005). The Treatment of Opioid Dependence. JHU Press. p. 63. ISBN 978-0-8018-8303-3. Retrieved 19 May 2012. 
  8. ^ Xiao Y, Smith RD, Caruso FS, Kellar KJ (October 2001). "Blockade of rat alpha3beta4 nicotinic receptor function by methadone, its metabolites, and structural analogs". The Journal of Pharmacology and Experimental Therapeutics 299 (1): 366–71. PMID 11561100. 
  9. ^ Hull JD, Scheinmann F, Turner NJ, (March 2003). "Synthesis of optically active methadones, LAAM and bufuralol by lipase-catalysed acylations". Tetrahedron: Asymmetry 14 (5): 567–576. doi:10.1016/S0957-4166(03)00019-3. 
  10. ^ US patent 6143933